Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.09M | $3.89M | $14.4M | $16.0M | $20.1M | $41.0M | $3.65M | $113M | $108M | $42.7M |
| Revenue growth | — | 256.5% | 270.3% | 10.9% | 25.6% | 104.0% | -91.1% | 3005.1% | -4.4% | -60.5% |
| Operating income | -$55.7M | -$102M | -$160M | -$208M | -$153M | -$127M | -$163M | -$68.0M | -$110M | -$215M |
| Operating margin | -5102.6% | -2630.1% | -1106.7% | -1303.4% | -763.9% | -310.1% | -4459.3% | -60.0% | -101.9% | -504.1% |
| Net income | -$55.7M | -$102M | -$147M | -$194M | -$150M | -$122M | -$162M | -$57.5M | -$97.0M | -$204M |
| Net margin | -5097.1% | -2619.6% | -1017.4% | -1211.5% | -746.7% | -298.4% | -4434.7% | -50.8% | -89.6% | -478.3% |
| EPS (diluted) | -$2.44 | -$3.85 | -$5.06 | -$5.72 | -$3.82 | -$2.36 | -$2.05 | -$0.54 | -$0.70 | -$1.21 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.9M | -$83.7M | -$22.9M | -$188M | -$116M | -$89.0M | -$128M | -$19.4M | -$151M | -$187M |
| Capital expenditures | $5.57M | $18.9M | $9.94M | $3.92M | $1.34M | $560K | $1.36M | $1.11M | $938K | $718K |
| Free cash flow | -$37.5M | -$103M | -$32.8M | -$192M | -$117M | -$89.6M | -$129M | -$20.5M | -$152M | -$188M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $150M | $143M | $175M | $147M | $184M | $151M | $88.5M | $200M | $302M | $602M |
| Total assets | $165M | $182M | $296M | $284M | $279M | $207M | $146M | $275M | $352M | $638M |
| Total liabilities | $22.1M | $34.4M | $215M | $213M | $189M | $167M | $184M | $227M | $135M | $112M |
| Shareholders' equity | $135M | $140M | $73.3M | $63.7M | $82.8M | $32.5M | -$45.1M | $39.6M | $210M | $518M |
| Retained earnings | -$90.5M | -$193M | -$340M | -$533M | -$683M | -$806M | -$967M | -$1.02B | -$1.12B | -$1.33B |
| Shares (wtd avg diluted) | 23.5M | 27.8M | 29.5M | 34.3M | 48.8M | 51.8M | 78.9M | 106M | 138M | 169M |
Every figure is extracted from Wave Life Sciences Ltd.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.